Comparison of Peptidic and Nonpeptidic δ-Opioid Agonists on Guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) Binding in Brain Slices from Sprague-Dawley Rats
- 1 March 2005
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 312 (3) , 1314-1320
- https://doi.org/10.1124/jpet.104.078741
Abstract
Previous studies have demonstrated that peptidic and nonpeptidic δ-opioid receptor agonists have different effects depending on the measure. For example, nonpeptidic δ-opioid agonists, but not peptidic agonists, produce convulsions in rats, and in vitro studies suggested that peptidic and nonpeptidic δ-opioid agonists might have differential mechanisms of receptor downregulation. The present study evaluated potential differences between peptidic and nonpeptidic δ-opioid agonists in their ability to activate G proteins using guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) autoradiography experiments in rat brain slices. The peptidic agonist [d-Pen2,d-Pen5]-enkephalin and the nonpeptidic agonist (+)BW373U86 [(+)-4-[α(R)-α-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide] demonstrated concentration-dependent increases in [35S]GTPγS binding that were attenuated by the δ-opioid antagonist naltrindole. (+)BW373U86 was more potent and efficacious than the peptidic agonist, and this difference remained consistent across brain regions where significant stimulation was observed. In addition, multiple δ-opioid compounds were evaluated for their agonist activity in this assay. These data suggested that differences between peptidic and nonpeptidic δ-opioid agonists in behavioral studies were most likely caused by differences in agonist efficacy. Finally, these data also revealed that [35S]GTPγS autoradiography could be used to compare efficacy differences among agonists across various brain regions in rat brain slices.Keywords
This publication has 42 references indexed in Scilit:
- δ-Opioid Agonists: Differential Efficacy and Potency of SNC80, Its 3-OH (SNC86) and 3-Desoxy (SNC162) Derivatives in Sprague-Dawley RatsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Nonpeptidic δ-opioid Receptor Agonists Reduce Immobility in the Forced Swim Assay in RatsNeuropsychopharmacology, 2002
- Comparison of Receptor Mechanisms and Efficacy Requirements for δ-Agonist-Induced Convulsive Activity and Antinociception in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2002
- The effects of δ agonists on locomotor activity in habituated and non-habituated ratsLife Sciences, 2000
- Hippocampal θ activity after systemic administration of a non-peptide δ-opioid agonist in freely-moving rats: relationship to D1 dopamine receptorsBrain Research, 1997
- Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implicationsTrends in Neurosciences, 1995
- Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(.alpha.R)-.alpha.-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide .delta. Opioid Receptor AgonistJournal of Medicinal Chemistry, 1994
- A selective .delta.1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for .delta.1 opioid receptor agonists and antagonistsJournal of Medicinal Chemistry, 1993
- Design of peptidomimetic .delta. opioid receptor antagonists using the message-address conceptJournal of Medicinal Chemistry, 1990
- Differential epileptogenic potentials of selective? and? opiate receptor agonistsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1983